SAB Biotherapeutics (SAB Biotherapeutics) Price-to-Operating-Cash-Flow : (As of Apr. 27, 2024)

View and export this data going back to 2021. Start your Free Trial

What is SAB Biotherapeutics Price-to-Operating-Cash-Flow?

As of today (2024-04-27), SAB Biotherapeutics's share price is $4.2499. SAB Biotherapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.27. Hence, SAB Biotherapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for SAB Biotherapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 5 years, SAB Biotherapeutics's highest Price-to-Operating-Cash-Flow Ratio was 52.22. The lowest was 0.00. And the median was 0.00.

SABS's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.65
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

SAB Biotherapeutics's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-1.99. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.27.

During the past 5 years, SAB Biotherapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was -36.50% per year. The lowest was -36.50% per year. And the median was -36.50% per year.

SAB Biotherapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for SAB Biotherapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SAB Biotherapeutics Price-to-Operating-Cash-Flow Chart

SAB Biotherapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

107.43

SAB Biotherapeutics Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of SAB Biotherapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, SAB Biotherapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SAB Biotherapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SAB Biotherapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where SAB Biotherapeutics's Price-to-Operating-Cash-Flow falls into.

SAB Biotherapeutics Price-to-Operating-Cash-Flow Calculation

SAB Biotherapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	4.2499	/	-4.266
	=

SAB Biotherapeutics's Share Price of today is $4.2499.
SAB Biotherapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.27.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

SAB Biotherapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of SAB Biotherapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

SAB Biotherapeutics (SAB Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SAB Biotherapeutics Inc (NAS:SABS) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

2100 East 54th Street North, Sioux Falls, SD, USA, 57104

Website

https://www.sabbiotherapeutics.com

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Executives

Eddie Joe Sullivan	director, 10 percent owner, officer: Chief Executive Officer	2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Michael King	officer: CHIEF FINANCIAL OFFICER	2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Samuel J Reich	director, officer: Executive Chairman	ACUITY PHARMACEUTICALS INC, 3701 MARKET STREET, PHILADELPHIA PA 19104
Sessa Capital Im, L.p.	director	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Andrew Moin	director	2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Sessa Capital (master), L.p.	director	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Im Gp, Llc	director	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
John Petry	director	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Gp, Llc	director	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Erick Lucera	director	138 THISTLE ROAD, NORTH ANDOVER MA 08145
David Charles Link	director	2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Christine E Hamilton	director, 10 percent owner	225 S MAIN AVE, P O BOX 5000, SIOUX FALLS SD 57117
Scott Giberson	director	2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Alexandra Kropotova	officer: Chief Medical Officer	RIVER OAKS TOWER, 8800 HSC PARKWAY, BYRAN TX 77807
Jeffrey G Spragens	director	4400 BISCAYNE BOULEVARD, SUITE 1500, MIAMI FL 33137